Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain
复制标题
DOI：
10.1016/j.lungcan.2007.03.011
复制
发表时间：
2007-09-01
期刊：
影响因子：
5.3
通讯作者：
Wei, Zhong
中科院分区：
文献类型：
--
作者：
Wu, Chi;Li, Yun Long;Wei, Zhong
背景：肺癌是大多数国家癌症死亡的主要原因。对于脑转移瘤等转移瘤患者，1年生存率为10%，其中大多数患者在1-3个月内死亡。非小细胞肺癌（NSCLC）的大型II期临床试验数据表明，腺癌的组织学亚型可能是吉非替尼治疗患者的预后因素。为了评估吉非替尼姑息治疗晚期腺癌和脑转移瘤患者的疗效，我们进行了第二阶段study.Patients和方法：符合条件的患者有组织学证实的腺癌和脑转移瘤证实与放射学研究。所有合格患者既往均接受过化疗。从2003年12月至2004年12月，40例患者每天接受250 mg剂量的吉非替尼。结果：总客观有效率为32%，疾病控制率为77%。总的来说，45%的患者出现症状改善。中位无进展生存期和总生存期分别为9.0个月和15.0个月。吉非替尼是湿润的，皮肤反应是最常见的毒性。结论：我们的数据表明吉非替尼在晚期肺腺癌和脑转移患者的姑息治疗中具有很有前途的活性。（D 2007 Elsevier爱尔兰有限公司保留AR权利。
Background: Lung cancer is the leading cause of cancer deaths in most countries. In patients with metastases, such as the brain, the 1-year survival is 10% and most of these patients die in 1-3 months. Data from large phase II trials of non-smatt cell lung cancer (NSCLC) suggested that the histologic subtype of adenocarcinorna may be a prognostic factor for patients treated with gefitinib. To evaluate the efficacy of gefitinib in palliative therapy for advanced patients with adenocarcinorna and brain metastases, we conducted a phase II study.Patients and methods: Eligible patients had histologically confirmed adenocarcinoma and brain metastases confirmed with radiological studies. All eligible patients had undergone chemotherapy previously. From December 2003 to December 2004, 40 patients received 250mg doses of gefitinib daily. The symptomatic response, survival, and toxicity were recorded.Results: The overall objective response rate was 32% with a disease control rate of 77%. Altogether, 45% of the patients experienced symptom improvement. The median progression-free survival and overall survival were 9.0 months and 15.0 months, respectively. Gefitinib was wett-toterated, with cutaneous reactions as the most frequent toxicity.Conclusions: Our data suggest that gefitinib has promising activity in palliative therapy for patients with advanced lung adenocarcinoma and brain metastasis. (D 2007 Elsevier Ireland Ltd. AR rights reserved.